Workflow
Oncocyte(OCX) - 2025 Q2 - Quarterly Report
OncocyteOncocyte(US:OCX)2025-08-12 04:11

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission File Number: 1-37648 Insight Molecular Diagnostics Inc. (Exact name of registrant as specified in its charter) (Sta ...